189290-58-2

Usage

Uses

Used in Pharmaceutical Industry:
N-(3-iodophenyl)-6,7-dimethoxyquinazolin-4-amine is used as an inhibitor for EGFR tyrosine kinase for the treatment of various cancers that are driven by the overactivation of the EGFR signaling pathway. Its high potency and selectivity make it a promising candidate for the development of targeted cancer therapies.
Used in Cancer Research:
In the field of cancer research, N-(3-iodophenyl)-6,7-dimethoxyquinazolin-4-amine is utilized as a valuable tool to study the role of EGFR in tumor growth and progression. By inhibiting the activity of EGFR, researchers can gain insights into the molecular mechanisms underlying cancer development and identify potential therapeutic targets for intervention.
Used in Drug Development:
N-(3-iodophenyl)-6,7-dimethoxyquinazolin-4-amine serves as a lead compound in the development of novel EGFR inhibitors for cancer treatment. Its structure can be further optimized to improve its pharmacokinetic properties, such as solubility, stability, and bioavailability, as well as to reduce potential side effects and toxicity.
Used in Drug Delivery Systems:
Similar to gallotannin, N-(3-iodophenyl)-6,7-dimethoxyquinazolin-4-amine can also be incorporated into drug delivery systems to enhance its therapeutic efficacy and bioavailability. Various carriers, such as organic and metallic nanoparticles, can be employed to improve the delivery of AG-1557 to cancer cells, potentially increasing its effectiveness and reducing systemic side effects.

in vitro

a pharmacophore model was developed using a dataset of 77 chemically diverse egfr inhibitors including ag-1557 using phase. statistically valid three dimensional quantitative structure activity relationship (3d-qsar) equations were generated. docking of the probable hits into the crystal structure of egfr was used as a second filter. calculation of adme properties of the probable hits arising out of docking further reduced the number of hits. the pharmacophore results indicated that the presence of two aromatic ring features, one acceptor feature, one donor feature and one hydrophobic feature were necessary for potent inhibitory activity. the generated pharmacophore resulted in a 3d-qsar model, with a correlation coefficient r2 of 0.9905 and q2 of 0.8764. docking studies as a second filter reduced the hits to 8. application of drug-likeness as a third filter gave 6 leads. ag-1557 was screening as an inhibitor of egfr tyrosine kinase with a predicted pic50 value of 8.62, which was comparable with its experimental determined value of 8.194 [1].

references

[1] joshi, a. ,gadhwal, m., and joshi, u.j. indentification of potential novel egfr inhibitors using a combination of pharmacophore and docking methods. int. j. pharm. pharmaceut. sci. 7(6), (2015).

Upstream product

• 26759-46-6 methyl 2-amino-4,5-dimethoxybenzoate 
• 13794-72-4 6,7-dimethoxy quinazolin-4-one 
• 626-01-7 3-Iodoaniline 
• 13790-39-1 6,7-dimethoxy-4-chloroquinazoline 

Relevant academic research and scientific papers

Synthesis and biological evaluation of allenic quinazolines using palladium-catalyzed hydride-transfer reaction

Allenic quinazolines 13a-h were designed as mimics of Tarceva, which is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and synthesized from the corresponding 4-(iodoanilino)quinazolines or 4-(iodophenoxy)quinazolines with N,N-dicyclohexylprop-2-ynylamine by the Sonogashira coupling followed by palladium-catalyzed hydride-transfer reaction. Cell growth inhibition of 13a-h toward A431, Kato III, SKBR3, and HepG2 was examined. Among the compounds synthesized, 13a showed a similar cell growth inhibition to Tarceva. Moreover, 13d and 13h exhibited a specific growth inhibition toward Kato III cells (IC50 = 12 and 4.7 μM, respectively), although a significant inhibition toward other three cell lines was not observed at a 100 μM concentration of compounds.